Patient characteristics
| Characteristic . | All patients (N = 53) . | Bortezomib maintenance (n = 14) . | Observation (n = 16) . | Not able to randomly assign (n = 23) . |
|---|---|---|---|---|
| Age, y | ||||
| Median (range) | 59 (41-75) | 54 (42-73) | 58 (43-72) | 63 (46-76) |
| ≥60 | 24 (45) | 6 (43) | 6 (38) | 12 (52) |
| Male sex | 41 (77) | 12 (86) | 13 (81) | 16 (70) |
| MIPI risk category | ||||
| Low | 25 (47) | 8 (57) | 8 (50) | 9 (39) |
| Intermediate | 19 (36) | 5 (36) | 7 (44) | 7 (30) |
| High | 9 (17) | 1 (7) | 1 (6) | 7 (30) |
| Elevated LDH | 21 (40) | 5 (36) | 6 (38) | 10 (43) |
| Nonnodal disease | 7 (13) | 2 (14) | 2 (13) | 3 (13) |
| Extranodal involvement | ||||
| Peripheral blood | 53 (100) | 14 (100) | 16 (100) | 23 (100) |
| Bone marrow | 51 (96) | 14 (100) | 15 (94) | 22 (96) |
| Gastrointestinal tract* | 40 (77) | 11 (78) | 14 (88) | 15 (68) |
| Histologic subtype | ||||
| Blastoid | 7 (13) | 1 (7) | 2 (12) | 4 (17) |
| Classic | 46 (87) | 13 (93) | 14 (88) | 19 (83) |
| Ki-67 status, % | ||||
| <10 | 12 (27) | 2 (18) | 3 (25) | 7 (33) |
| 10-29 | 23 (52) | 7 (64) | 5 (42) | 11 (52) |
| ≥30 | 9 (20) | 2 (18) | 4 (33) | 3 (14) |
| Missing | 9 | 3 | 4 | 2 |
| Characteristic . | All patients (N = 53) . | Bortezomib maintenance (n = 14) . | Observation (n = 16) . | Not able to randomly assign (n = 23) . |
|---|---|---|---|---|
| Age, y | ||||
| Median (range) | 59 (41-75) | 54 (42-73) | 58 (43-72) | 63 (46-76) |
| ≥60 | 24 (45) | 6 (43) | 6 (38) | 12 (52) |
| Male sex | 41 (77) | 12 (86) | 13 (81) | 16 (70) |
| MIPI risk category | ||||
| Low | 25 (47) | 8 (57) | 8 (50) | 9 (39) |
| Intermediate | 19 (36) | 5 (36) | 7 (44) | 7 (30) |
| High | 9 (17) | 1 (7) | 1 (6) | 7 (30) |
| Elevated LDH | 21 (40) | 5 (36) | 6 (38) | 10 (43) |
| Nonnodal disease | 7 (13) | 2 (14) | 2 (13) | 3 (13) |
| Extranodal involvement | ||||
| Peripheral blood | 53 (100) | 14 (100) | 16 (100) | 23 (100) |
| Bone marrow | 51 (96) | 14 (100) | 15 (94) | 22 (96) |
| Gastrointestinal tract* | 40 (77) | 11 (78) | 14 (88) | 15 (68) |
| Histologic subtype | ||||
| Blastoid | 7 (13) | 1 (7) | 2 (12) | 4 (17) |
| Classic | 46 (87) | 13 (93) | 14 (88) | 19 (83) |
| Ki-67 status, % | ||||
| <10 | 12 (27) | 2 (18) | 3 (25) | 7 (33) |
| 10-29 | 23 (52) | 7 (64) | 5 (42) | 11 (52) |
| ≥30 | 9 (20) | 2 (18) | 4 (33) | 3 (14) |
| Missing | 9 | 3 | 4 | 2 |
Data are presented as n (%) unless otherwise indicated.
LDH, lactate dehydrogenase; MIPI, Mantle Cell Lymphoma International Prognostic Index.
One patient in the group that could not be randomly assigned was not evaluated for gastrointestinal tract involvement.